Vigil Neuroscience (Vigil Neuroscience) Interest Coverage : N/A (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Vigil Neuroscience Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Vigil Neuroscience's Operating Income for the three months ended in Dec. 2023 was $-23.86 Mil. Vigil Neuroscience's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Vigil Neuroscience Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for Vigil Neuroscience's Interest Coverage or its related term are showing as below:

VIGL's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 138.73
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Vigil Neuroscience Interest Coverage Historical Data

The historical data trend for Vigil Neuroscience's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Vigil Neuroscience Interest Coverage Chart

Vigil Neuroscience Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Interest Coverage

No Debt

N/A

No Debt

N/A

Vigil Neuroscience Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Coverage	Get a 7-Day Free Trial										N/A	N/A	N/A	N/A	No Debt

Competitive Comparison of Vigil Neuroscience's Interest Coverage

For the Biotechnology subindustry, Vigil Neuroscience's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vigil Neuroscience's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vigil Neuroscience's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Vigil Neuroscience's Interest Coverage falls into.

Vigil Neuroscience Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Vigil Neuroscience's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Vigil Neuroscience's Interest Expense was $0.00 Mil. Its Operating Income was $-88.87 Mil. And its Long-Term Debt & Capital Lease Obligation was $12.95 Mil.

GuruFocus does not calculate Vigil Neuroscience's interest coverage with the available data.

Vigil Neuroscience's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Vigil Neuroscience's Interest Expense was $0.00 Mil. Its Operating Income was $-23.86 Mil. And its Long-Term Debt & Capital Lease Obligation was $12.95 Mil.

GuruFocus does not calculate Vigil Neuroscience's interest coverage with the available data.

The higher the ratio, the stronger the company's Financial Strength is.

Vigil Neuroscience (NAS:VIGL) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Vigil Neuroscience Interest Coverage Related Terms

Thank you for viewing the detailed overview of Vigil Neuroscience's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Vigil Neuroscience (Vigil Neuroscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vigil Neuroscience Inc (NAS:VIGL) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Forge Road, Suite 700, Watertown, MA, USA, 02472

Website

https://www.vigilneuro.com

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families.

Executives

Ivana Magovcevic-liebisch	director, officer: President and CEO	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Christopher Silber	officer: Chief Medical Officer	C/O VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472
Budd Haeberlein Samantha L.	director	VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472
Gray David L. F.	officer: Chief Science Officer	VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472
Spyridon Papapetropoulos	officer: Chief Medical Officer	C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 1000, EMERYVILLE CA 94608
Suzanne Louise Bruhn	director	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Clay Thorp	director	C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701
Evan Thackaberry	officer: SVP, Head of Early Development	VIGIL NEUROSCIENCE, INC., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Jennifer Lynn Ziolkowski	officer: Chief Financial Officer	C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Christopher Verni	officer: General Counsel	VIGIL NEUROSCIENCE, INC., 1 BROADWAY, 7TH FLOOR, SUITE 07-300, CAMBRIDGE MA 02142
Mary Thistle	director	C/O VIACELL, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Vida Ventures Gp Iii, L.l.c.	10 percent owner	455 MARKET STREET, SUITE 1420, SAN FRANCISCO CA 94105
Northpond Ventures Gp, Llc	10 percent owner	7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
Stefan Vitorovic	director	C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Bruce Booth	director	890 WINTER STREET, SUITE 320, WALTHAM MA 02451